Business Services Industry
Resverlogix Corp.: RVX208 Unique MOA Positions it as a Leader in ApoA-I/HDL Marketplace; Hundreds of thousands of patients in key landmark trials demonstrate that enhanced ApoA-I significantly reduces cardiovascular disease risk.
Canadian Corporate News, December, 2006
 | Content provided in partnership with |  |
CALGARY, ALBERTA, Dec 5, 2006 (CCNMatthews via COMTEX) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action (MOA) is well positioned in the emerging HDL therapeutic market segment for reducing atherosclerosis and heart disease.
- Most Popular Articles in Business
- Research and Markets : Tesco Plc - SWOT Framework Analysis
- Do Us a Flavor - Ben & Jerry's Issues a Call for Euphoric New Flavors
- eBay made easy: ready to start an eBay business? These 5 simple steps will ...
- Katrina's lawsuit surge: a legal battle to force insurers to pay for flood ...
- Wal-Mart's newest distribution center opened last month near the southwest ...
- More »
Given recent events in the marketplace regarding cholesterol management drugs, Resverlogix verifies that its lead candidate will be tested in humans Q1 2007. It is imperative to understand that one of the most important factors for a successful drug target is to have large ...
Read the rest of this article with a Free Trial at HighBeam Research.Find Research Guides for:
Find Featured Titles for: Autos
Most Popular Articles in Business
- Research and Markets : Tesco Plc - SWOT Framework Analysis
- Do Us a Flavor - Ben & Jerry's Issues a Call for Euphoric New Flavors
- eBay made easy: ready to start an eBay business? These 5 simple steps will ...
- Katrina's lawsuit surge: a legal battle to force insurers to pay for flood ...
- Wal-Mart's newest distribution center opened last month near the southwest ...
- More »